Thyroglobulin Antibody Test

Your TSH (thyroid stimulating hormone) and thyroid hormone levels can look perfectly normal for years while your immune system is quietly mounting an attack on your thyroid gland. Thyroglobulin antibody, or TgAb, is one of the earliest signals that this attack is underway. In the NHANES III survey of the US population, about 10% of disease-free adults tested positive for TgAb, and prevalence climbed with age and was higher in women than men.

This test measures whether your body is making antibodies against thyroglobulin, a large protein your thyroid uses as a building block for thyroid hormones. When TgAb shows up in your blood, it means your immune system has lost tolerance to your own thyroid tissue. That process can simmer for years before your thyroid function actually declines, giving you a window to act.

What TgAb Tells You About Thyroid Autoimmunity

TgAb is an antibody protein made by B cells (a type of white blood cell) when your immune system mistakenly recognizes thyroglobulin as foreign. Thyroglobulin is a very large protein produced exclusively by thyroid cells. It is the raw material your thyroid converts into the hormones T3 and T4.

A positive TgAb result signals ongoing or past autoimmune activity against your thyroid. In Hashimoto's thyroiditis, the most common cause of hypothyroidism, TgAb is found in 60% to 80% of cases, often alongside TPOAb (thyroid peroxidase antibody, the other main thyroid autoantibody). But TgAb can appear on its own. In a study of 749 adults with overweight or obesity, adding TgAb to TPOAb testing identified autoimmune thyroiditis in 20% of the group, including cases that TPOAb alone would have missed.

TgAb is also more common in women than men and increases with age. In a study of over 5,000 children followed from birth, the earliest appearance of TgAb in blood occurred at just 15 months of age, and girls were affected more often than boys. A family history of autoimmune thyroid disease more than doubled the risk of developing TgAb.

Hashimoto's Thyroiditis and Hypothyroidism Risk

The strongest clinical use of TgAb in general health is predicting future thyroid dysfunction. In a 13-year follow-up of 1,184 Australian adults, researchers found that a TgAb level above 22 kIU/L (a unit measuring antibody concentration in blood) was the threshold that best predicted who would develop hypothyroidism over the next decade. When combined with a TSH above 2.5 mIU/L, the combination identified people at meaningfully elevated long-term risk.

However, after adjusting for age, sex, and TSH, TgAb in the modest range of 22 to 55 kIU/L was not independently predictive of hypothyroidism on its own. The real power comes from combining TgAb with TSH and, ideally, TPOAb. In the TEDDY birth cohort, children who developed both TgAb and TPOAb simultaneously had about 6 times the risk of progressing to clinical thyroid disease compared to those who developed TPOAb first. That finding held up after adjusting for sex, genetics, and family history.

Connections to Other Autoimmune Conditions

TgAb rarely travels alone. In a study of 814 people with type 1 diabetes, 29% tested positive for thyroid autoantibodies (TPOAb and/or TgAb), and these antibodies clustered with other autoantibodies that target specific organs, including those linked to celiac disease and adrenal insufficiency. Children newly diagnosed with type 1 diabetes should be screened for thyroid autoimmunity, since thyroid autoantibodies at diagnosis predict future autoimmune thyroid disease.

A meta-analysis of 40 studies found that women with PCOS (polycystic ovary syndrome) had about twice the odds of testing positive for TgAb compared to controls. TgAb levels were also significantly higher in the PCOS group, even after matching for body weight. A separate meta-analysis of studies examining psoriasis and thyroid autoimmunity also found TgAb positivity was about twice as common in people with psoriasis compared to controls.

TgAb and Thyroid Cancer Follow-Up

About 20% to 40% of people with differentiated thyroid cancer (the most common form) have TgAb. This matters because the primary blood marker used to monitor for thyroid cancer recurrence after surgery is thyroglobulin (Tg). TgAb can bind to thyroglobulin in the lab tube and cause the test to read falsely low or even undetectable, even when cancer is still present. Standard thyroglobulin blood tests are particularly vulnerable to this interference.

When TgAb makes thyroglobulin unreliable, the TgAb level itself becomes a stand-in marker for tracking cancer. After thyroid surgery and radioiodine treatment, a steadily falling TgAb level generally reflects successful treatment. Stable or rising TgAb suggests persistent or recurrent disease and warrants further evaluation, typically beginning with a neck ultrasound. In one study, a fall of 47% or more in TgAb over the first year after radioiodine meant that about 97% of those patients were truly disease-free.

Immune Checkpoint Inhibitor Therapy

If you are being treated with immune checkpoint inhibitors (ICIs) for cancer, TgAb has a specific predictive role. These drugs work by releasing the brakes on your immune system, which can cause it to attack your own organs, including the thyroid. In a study of 122 melanoma patients on checkpoint inhibitors, 42% of those with pre-existing thyroid antibodies developed significant thyroid dysfunction, compared to far fewer of those without antibodies. A larger analysis of 221 cancer patients on checkpoint inhibitors found that pre-existing thyroid antibodies conferred about 27 times the odds of developing thyroid dysfunction during treatment.

In another cohort of 516 patients on PD-1 blockers (a type of checkpoint inhibitor), the pattern of TgAb and TPOAb positivity at baseline stratified risk for both thyrotoxicosis (an overactive thyroid) and hypothyroidism during treatment. Checking TgAb before starting these drugs gives you and your oncologist a head start on monitoring.

Reference Ranges

TgAb is primarily interpreted as positive or negative rather than graded into risk tiers. Cutpoints vary substantially between assay manufacturers, which is one of the most important things to understand about this test. Two different labs can give you two different answers from the same blood sample. The table below provides general orientation based on published research, not universal clinical targets.

Always compare your results within the same lab using the same assay over time. A 13-year community study found that the optimal predictive threshold for future hypothyroidism was about 22 kIU/L, while the standard lab upper reference limit in that study was 55 kIU/L. These numbers will differ depending on your lab's platform. The trend in your TgAb, whether it is falling, stable, or rising, matters far more than any single reading.

When Results Can Be Misleading

The biggest source of error with TgAb is not your biology but the lab method itself. Different TgAb assays can classify the same blood sample as positive on one platform and negative on another. In one study comparing multiple commercial assays, results were highly discordant, particularly in patients with papillary thyroid cancer. If your lab changes its TgAb assay platform between visits, your result can appear to jump or drop for purely technical reasons.

• Assay platform changes: Switching labs or assay manufacturers during follow-up can flip your TgAb status from positive to negative (or vice versa) without any real change in your immune activity. Always retest at the same lab when tracking trends.
• Low-level TgAb missed by standard cutoffs: Some manufacturer-recommended cutoffs are too high to catch all antibodies that interfere with thyroglobulin testing. You can have a 'negative' TgAb by the lab's standard and still have enough antibody to make your thyroglobulin result falsely low.
• Heterophile antibodies: These are unrelated antibodies (sometimes produced after exposure to animal proteins) that can cause falsely high thyroglobulin readings, mimicking cancer recurrence. They are uncommon but can confuse interpretation when clinical findings and lab results do not match.
• Pregnancy: TgAb naturally falls during pregnancy due to immune suppression, reaching its lowest point in the third trimester, then rebounds sharply after delivery. A single reading during or shortly after pregnancy may not represent your baseline.